NAD⁺ (Nicotinamide Adenine Dinucleotide): A Foundational Coenzyme in Metabolic and Aging Research

Research summary. NAD⁺ (nicotinamide adenine dinucleotide) is not a peptide but is included alongside peptides in research-supplier catalogues because of its central role in mitochondrial bioenergetics, sirtuin biology, and aging-related research. NAD⁺ is a dinucleotide cofactor consisting of two nucleotides — one carrying nicotinamide and the other adenine — joined through their phosphate groups. It is one of the most fundamental cofactors in mammalian biochemistry, participating as an electron carrier in catabolic redox reactions and as a substrate consumed by sirtuins, PARPs, and CD38.

Molecular profile

• Class: Pyridine dinucleotide cofactor (not a peptide)
• Molecular formula: C₂₁H₂₇N₇O₁₄P₂
• Molecular weight: ~663.4 g/mol
• PubChem CID: 925
• CAS Number: 53-84-9
• Synonyms: β-NAD, NAD, nicotinamide adenine dinucleotide
• Related precursor compounds: Nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), nicotinic acid, nicotinamide

Biological role

NAD⁺ functions in two distinct biochemical roles:

• Redox cofactor. As an electron carrier, NAD⁺ accepts a hydride during catabolism (for example in glycolysis and the TCA cycle) to become NADH, which then donates electrons to the mitochondrial electron transport chain at complex I. The NAD⁺/NADH couple is the dominant cellular electron-transfer redox pair and is central to ATP production.
• Consumed cosubstrate for NAD-dependent enzymes. NAD⁺ is also consumed (not just cycled) by three major enzyme families: sirtuins (SIRT1–SIRT7), poly-ADP-ribose polymerases (PARPs), and CD38/CD157 NAD-glycohydrolases. Each cleaves NAD⁺ during catalysis. This consumed-substrate role is the mechanistic basis for the well-documented decline in cellular NAD⁺ levels with age — competing demands deplete a limited pool.

Mechanism of action in aging-related research

The "NAD⁺ decline" hypothesis of aging is built on three observations: (1) tissue NAD⁺ levels decline with age across multiple species; (2) sirtuin activity is NAD⁺-dependent and declines proportionally; and (3) restoring NAD⁺ levels through precursor administration reverses several aging phenotypes in rodent models.

Key downstream consequences of NAD⁺ availability include:

• Sirtuin-mediated deacetylation of metabolic and mitochondrial transcription factors (PGC-1α, FOXO3, p53, others).
• PARP-mediated DNA-damage response, which both consumes NAD⁺ and is required for genome stability.
• CD38-mediated NAD⁺ consumption, which has emerged as a major contributor to age-related NAD⁺ decline; CD38 inhibition is itself an active drug-development target.
• Mitochondrial unfolded protein response and electron-transport-chain function, both NAD⁺-sensitive.

Preclinical research highlights

NAD⁺ precursor administration in rodents. Studies using nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) — both efficient NAD⁺ precursors — have reported tissue NAD⁺ restoration, improved mitochondrial function, improved insulin sensitivity, and modest extensions of healthspan endpoints in aged mice [1].

Vascular biology. Rodent studies have reported that NAD⁺ precursor administration restores endothelial function and reduces age-associated arterial stiffness.

Skeletal muscle. Aged rodents receiving NAD⁺ precursors have shown improvements in mitochondrial function, exercise endurance, and muscle stem-cell function in published studies.

Neuronal and cognitive endpoints. Research has reported neuroprotective effects in models of neurodegeneration, with mechanisms attributed to sirtuin activation, mitochondrial support, and improvement of cellular energy status.

Hepatic and metabolic endpoints. NAD⁺ precursor administration has been associated with improvements in hepatic insulin sensitivity and reductions in hepatic steatosis in diet-induced obesity models.

Translational considerations and current human data

Translation of rodent NAD⁺ research to human clinical effect has been more measured than the strength of the rodent literature might suggest. Published human NMN and NR trials have reliably demonstrated elevations in blood NAD⁺ measures with oral precursor administration but have produced more variable results on functional endpoints. Trials in conditions including ischaemia-reperfusion, ataxia-telangiectasia, and Parkinson's disease have produced mixed signals at the time of writing.

NAD⁺ itself is poorly orally bioavailable; most clinical NAD⁺-elevating strategies use precursor compounds (NMN, NR) rather than NAD⁺ directly.

Current research status

NAD⁺ as a metabolite is endogenous and not subject to drug approval. NAD⁺ precursors (NR, NMN) are sold variously as dietary supplements; FDA enforcement positions on NMN as a dietary ingredient have been a moving target and should be verified against current FDA guidance. No oral NAD⁺ or NAD⁺-precursor product has been approved as a drug in the United States at the time of writing.

For research-supplier contexts, NAD⁺ and its precursors are supplied as research-grade compounds and are not intended for self-administration.

Key takeaways for researchers

• NAD⁺ is a pyridine dinucleotide cofactor, not a peptide; it functions as both a redox cofactor and a consumed substrate for sirtuins, PARPs, and CD38.
• Tissue NAD⁺ levels decline with age, and the "NAD⁺ decline" hypothesis is a major framework in aging-related research.
• Reported preclinical effects of NAD⁺ precursor administration span vascular, muscular, neuronal, and hepatic endpoints.
• Translation to human clinical effect has been more measured than rodent data; most strategies use NR or NMN precursors rather than NAD⁺ directly.
• No oral NAD⁺ or NAD⁺-precursor product has been approved as a drug in the United States at the time of writing.

References

1. Mills KF, Yoshida S, Stein LR, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016;24(6):795–806.
2. Yoshino J, Baur JA, Imai SI. NAD⁺ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab. 2018;27(3):513–528.

---

This article is provided for educational and research purposes only. NAD⁺ and NAD⁺ precursors are research compounds. Nothing in this article constitutes medical advice or a recommendation for use. All work involving these compounds should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.